Your current web browser is outdated. For best viewing experience, please consider upgrading to the latest version.

Donation - Other Level

Please use the quantity box to donate any amount you wish. Sign Up to Donate

Contact

Send a question or comment using the form below. This message may be routed through support staff.

Email Article

Password Reset Request

Register


Add a topic or expert to your feed.

Following

Follow Experts & Topics

Stay on top of our work by selecting topics and experts of interest.

Experts
Topics
Project
On The Ground
ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed
ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed

Manhattan Institute

search
Close Nav
Share this commentary on Close

MI Responds: Ohio Votes Down Government-Mandated Drug Prices

commentary

MI Responds: Ohio Votes Down Government-Mandated Drug Prices

November 8, 2017
Health PolicyDrug Development

By voting “no” on Issue 2, the people of Ohio have sent a clear and powerful message – lower drug prices can’t be mandated by government fiat. The American people deserve access to affordable drugs, but they understand that price controls are not a real solution.

I hope the rejection of Issue 2 will encourage policymakers to give up on price control schemes, and instead focus on increasing competition and price transparency across Ohio’s health care markets.  Competition is the right way to make lifesaving, and life-improving, more affordable for patients.

MI Responds features real-time commentary from MI scholars on breaking news and developing issues. 

______________________

Dr. Tom Coburn is the Nick Ohnell Fellow at the Manhattan Institute and a former two-term U.S. Senator from Oklahoma.

Saved!
Close